Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses

Volker Gerdts*, Alexander Zakhartchouk

Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, 120 Veterinary Rd., Saskatoon, Saskatchewan, S7N5E3, Canada

1. Swine Coronaviruses

Coronaviruses were first described in the mid-1960s and subsequently isolated from a number of species including man, mice, swine and chicken. These viruses share a common morphological characteristic, a fringe of club-shaped projections, 12–24 nm long, around a pleomorphic 60–220 nm viral particle, having a resemblance to a solar corona (Masters, 2013). Coronaviruses infect humans and various animal species, causing respiratory, gastrointestinal and neurological diseases as well as hepatitis. Prominent examples include the severe acute respiratory syndrome virus (SARS-CoV), middle-eastern respiratory syndrome virus (MERS-CoV) and the feline infectious peritonitis virus (FIPV), to name a few.

Swine coronaviruses can be divided into respiratory (PRCoV) and enteropathogenic coronaviruses such as transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV) and porcine deltacoronavirus (PDCoV). The latter have similar epidemiological, clinical and pathological features. The family *Coronaviridae* is currently divided into four genera: *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus* and *Deltacoronavirus*. TGEV and PEDV belong to the *Alphacoronavirus* genus, whereas PDCoV belongs to genus of *Deltacoronaviruses*.

Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses with the largest RNA genome of approximately 30 kb reported to date. The genomic RNA includes 5’ and 3’ untranslated regions (UTR), and it is capped and polyadenylated. Open reading frame (ORF) 1a and ORF1ab occupy the 5’ two-thirds of the genome and encode two replicate polyproteins (pp1a and pp1ab). Expression of pp1ab protein requires a ribosomal frameshift during translation of the genomic RNA. Produced polyproteins are proteolytically cleaved into 16 nonstructural proteins, nsp1 through nsp16 by the protease activity of nsp3 and nsp5. The 3’-proximal one-third of the genome encodes four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Some betacoronaviruses have an additional membrane protein, hemagglutinin esterase (HE). Interspersed between these genes are genes encoding accessory proteins. The number of these genes varies between different coronaviruses. For instance, TGEV has 3 accessory genes, PDCoV has 2, whereas PEDV has only one (Fig. 1).

The viral RNA genome is packaged by the N protein into a helical nucleocapsid. In addition to the structural role, the N protein prolongs S-phase cell cycle, induces endoplasmic reticulum stress, up-regulates interleukine-8 expression and antagonizes type I interferon production (Ding et al., 2014; Xu et al., 2013b). The S protein, which forms peplomers on the virion surface, mediates binding to host receptors and membrane fusion. It can be divided into S1 and S2 domains. In some coronaviruses the S protein is processed into S1 and S2 fragments by cellular proteases or trypsin (Belouzard et al., 2012; Wicht et al., 2014). The S protein is a major target for virus neutralizing antibodies (Chang et al., 2002; Reguera et al., 2012). The M protein is the most abundant virion component and also contains conserved linear B-cell epitopes (Zhang et al., 2012). The E protein is responsible for the assembly of virion, and it causes endoplasmic reticulum stress and interleukin-8 expression.
up-regulation (Xu et al., 2013a). Accessory genes are dispensable for virus growth in vitro, but they may play an important role in the virus survival in the infected host. Indeed, the product of the TGEV accessory gene ORF7 reduces the expression of genes involved in the antiviral defense of the immune system, e.g. the interferon response, and inflammation (Cruz et al., 2011). The ORF3 protein of PEDV functions as an ion channel, and it is thought to be related with virulence of PEDV (Song et al., 2003; Wang et al., 2012). One of the PEDV non-structural proteins, nsP1, was shown to be a type I interferon suppressor (Zhang et al., 2016a). Interestingly, PDCoV lacks the nsP1 gene.

2. Pathogenesis and clinical disease

Coronaviruses target predominantly type I and II pneumocytes (PRCoV) or villous- and crypt enterocytes in the intestine (TGEV, PEDV and PDCoV). PEDV also infection Goblet cells in the small intestine (Jung and Saif, 2015). In addition, infection of alveolar macrophages and lamina propria macrophages has been shown for some but not all swine coronaviruses (Laude et al., 1984; Park and Shin, 2014). Entrance of the virus into the target cells is mediated by a series of receptor ligand interactions including heparin sulfate (Huan et al., 2015) and aminopeptidase N (APN) (Chen et al., 1996; Li et al., 2007). Importantly, the expression levels of aminopeptidase N appear to correlate with the level of infection, at least for PEDV. The higher the expression levels the more severe is the infection (Li et al., 2007; Zhang and Yoo, 2016). As a result, it may be perceivable that pigs born with lower APN levels in the brush border may be more resistant to PEDV than pigs with higher levels.

Enteric infections with TGEV and PEDV are characterized by severe diarrhea, vomiting and dehydration with high morbidity and mortality especially in piglets less than two weeks of age. In contrast, infections with respiratory coronaviruses cause very mild and transient disease in pigs of all ages, which often get unnoticed by the producer. Unless complicated by concurrent infections, PRCoV infections are only short lasting with temporary phases of coughing and respiratory distress. However, PRCoV can become a more significant problem during co-infections with other pathogens such as the porcine reproductive and respiratory syndrome virus PRRSV (Jung et al., 2009).

Infection of enterocytes with PEDV results in villous atrophy which can lead to malabsorption, diarrhea and anorexia. Within 24–48 h post infection, vomiting may occur, which typically does not last longer than 2–3 days post infection. Diarrhea can be found within 24 to 36 h post infection depending on the dose of the virus and the age of the piglets. Diarrhea typically lasts for about 5–8 days, but can last longer, and results in severe weight loss that often cannot be made up during the normal production cycle. Viral shedding is highest between days 3–5, but can last for days to weeks post infection. Surviving piglets start to recover around 6–8 days post infection, typically around the same time when proliferation of the crypt epithelium and regeneration of the villi occurs. Similarly, TGEV infects villous enterocytes and causes disease that clinically is indistinguishable from PEDV. Mortality rates are highest in young piglets, often reaching about 100%. In contrast, infection with PDCoV causes milder infections in piglets between 3 and 5 weeks of age. Diarrhea, vomiting and anorexia can be found in infected animals. In general, infected animals display much milder signs compared to infections with PEDV and TGEV.

3. Immunity to swine coronaviruses

The innate immune response to enteric coronaviruses in pigs is characterized by a rapid antiviral response in the intestine, including the release of interferons, nuclear factor κB and other antiviral molecules (Chatttha et al., 2015; Jung and Saif, 2015; Sang et al., 2010). Pigs can produce three types of interferons (Sang et al., 2014): Type I interferons include well known interferons such as interferon α and β (IFN-α/β) and in pigs are encoded by as many as 17 different genes. The only type II interferon in pigs is IFN-γ. Type III interferons include IFN-λ1 (interleukin 29; IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B) and IFN-λ4 (Kotenko et al., 2003; Park et al., 2012; Prokunina-Olsson et al., 2013; Sheppard et al., 2003; Zhang and Yoo, 2016). Their functions are unknown in pigs. Especially type I and III interferons are used by the host to counteract viral infections. In response, most viruses including PEDV and TGEV have developed strategies to evade and interfere with the interferon response. Several viral proteins, including structural and non-structural proteins have been identified for PEDV and TGEV that can suppress the interferon response. For an excellent review on the evasion of immunity by porcine coronaviruses please see (Zhang and Yoo, 2016).

The adaptive immune response to swine enteric coronoviruses is based on secretory antibodies and cytotoxic T cells. These include secretory IgA antibodies (SIgA) that are produced by antibody-secreting cells in the lamina propria of the mucosal tissues and systemic antibodies such as IgG and IgM are found in serum and intestinal tissues and some isotypes can be transusaded across the mucosal epithelium into the lumen (Chatttha et al., 2015; Horton and Vidarsson, 2013). The cellular response to swine coronaviruses is characterized by T helper cells that are supporting the production of antibodies and cytotoxic T cells that are targeting virus infected epithelial cells. In pigs, these are predominantly yd-
cells, most of which can be found within the intraepithelial layer (Bonneville et al., 2010). The majority of T cell epitopes are located in the Spike and nucleoprotein of coronaviruses (Channappanavar et al., 2014; Saif, 2004; Sestak et al., 1999). Additionally, CD8 T cell epitopes have been found in the membrane protein of the human SARS-CoV (Yang et al., 2006).

In neonatal piglets, the main mechanism of protection is mediated by lactogenic immunity. During lactation, IgA, IgG and IgM are passively transferred to the piglet via colostrum and milk (Bohl and Saif, 1975; Saif and Bohl, 1979, 1983; Salmon et al., 2009). Colostrum contains predominantly IgG, which is transudated from sow serum and absorbed by the piglet within the first 24–48 h of life. Secretory IgA is predominantly found in milk, after transitioning from colostrum to milk around 3–4 days of age (Langel et al., 2016). IgA is produced by antibody secreting cells in the mammary gland, and it was shown many years ago by Bohl and Saif (Bohl et al., 1972a) that these cells migrate from the gut to the mammary gland at the end of pregnancy. This was confirmed by others in a variety of species and chemokines such as CCL28 and others have been found responsible for recruiting these antibody secreting cells to the mammary gland (Bourges et al., 2008; Lazarus et al., 2003; Meurens et al., 2006, 2007; Wilson and Butcher, 2004). Thus, in order to enhance the level of maternal immunity the oral route seems to be the most obvious choice for vaccinating the sow. Indeed, most vaccines for enteric coronaviruses are designed to induce lactogenic immunity by vaccinating the sow, however, most of them are administered via systemic injection. In the absence of effective vaccines for PEDV, many producers are currently using a lock-down of the barn combined with feeding back infectious live virus to pregnant sows. However, the duration of immunity often does not extend more than a few years (Table 1), depending on the type of vaccine being used with live vaccines typically providing longer lasting immunity. Even after feed-back, immunity starts to wane after a relatively short period of time, often even less than a few months. For an excellent review of the role of lactogenic immunity for PEDV see (Langel et al., 2016). In addition to antibodies, the colostrum also contains innate effector molecules such as defensins and antimicrobial peptides, interleukins and cytokines (Bandrick et al., 2014; Hlavova et al., 2014; Mair et al., 2014; Nechvatalova et al., 2011; Salmon et al., 2009).

The level of cross-protection is somewhat unclear for coronaviruses. For PEDV, Goede et al. reported that 3-day old piglets born to sows that had been infected with a mild strain of PEDV seven months previously, were protected against infection with a more virulent strain of PEDV (Goede et al., 2015). In this experiment the sows were challenged with a more virulent PEDV virus at day 109 of gestation, and orally re-challenged when the piglets were three days old. None of the sows displayed significant clinical symptoms. The piglets were orally challenged with 1 ml of mucus scrapings of the more virulent PEDV. While mortality and morbidity rates varied significantly amongst the piglets in each group, the overall morbidity and mortality was reduced in piglets born to sows that had been pre-exposed to PEDV.

### 4. Vaccines for TGEV and other coronaviruses

In the 90s, TGEV was responsible for severe economic losses around the globe. Several vaccine technologies were developed and commercialised. By administration to sows, the importance of lactogenic immunity was established (Bohl et al., 1972b; Saif and Bohl, 1983). However, with a disappearance of the disease in many parts of the world, fewer vaccines are now commercially available in North America and Europe (Table 2). Most current commercial TGEV vaccines are live attenuated vaccines that are given to the sow during gestation in order to provide lactogenic immunity to the newborn piglet. These vaccines are often available as bi- or trivalent vaccines combined with rotavirus, PEDV and/or Escherichia coli. Experimental vaccines include novel DNA vaccines, vectored vaccines and recombinant vaccines (Table 1). For example, the porcine adenovirus was used to deliver the TGEV spike protein (Tuboly and Nagy, 2001). Yuan et al. used the swine pox virus to express the A epitope of the spike protein (Yuan et al., 2015). DNA plasmids were generated for both PEDV and TGEV for the development of a DNA vaccine (Meng et al., 2013). Recombinant proteins (spike and nucleocapsid) have been extensively evaluated as recombinant vaccine following expression in bacteria, yeast and plants. Many of these are being assessed for their potential to mucosal immunity after oral administration.

### Table 1

| Vaccine type | Development | Advantages | Disadvantages | Coronavirus antigen |
|--------------|-------------|------------|---------------|---------------------|
| Inactivated virus (Baek et al., 2016; Frederikson et al., 2014; Berube et al., 2015) | Virions are inactivated with chemicals. | Easy to prepare; cannot cause disease if properly inactivated. | Can induce Th2-skewed immune response; needs adjuvant. | Whole virus |
| Live-attenuated virus (de Arriba et al., 2002; Sato et al., 2011) | Genomes are mutated using multiple passages in Vero cells. | Inexpensive; strong cellular and humoral immune responses; can be given orally. | Reversion to virulence; can still cause some disease; protection is dose dependent. | Whole virus |
| Viral vectored (Yuan et al., 2015; Tuboly and Nagy, 2001). Subunit (Oh et al., 2014; Makadiya et al., 2016; Bae et al., 2003) | Unrelated viral genome (Poxivirus, Adenovirus) engineered to express the gene of interest. Antigen is expressed in mammalian, baculovirus, yeast or plant cells. | Strong cellular and humoral immune responses; intrinsic adjuvant properties; can be given orally. Cannot cause disease from viral infection; can generate high-titer neutralizing antibodies. | Expensive; needs adjuvant; protection can be incomplete. | Spike protein |
| DNA vaccines (Zhang et al., 2016b; Meng et al., 2013) | Genes encoding antigens are cloned into plasmid expression vector. | Cannot cause disease from viral infection; can be given orally when introduced into Lactobacillus or Salmonella. | Th1-skewed immune response when used alone. | Spike, nucleocapsid or membrane proteins |
| Viral replicating particles vaccine (Mogler et al., 2014a,b) | Replicon RNA containing gene of interest is packaged into alphavirus virion particles. | Cannot cause disease from viral infection; intrinsic adjuvant properties; high level of antigen expression. | Oral delivery has not been demonstrated. | Spike protein |
Table 2
Vaccines for TGEV and PEDV.

| Virus | Region/ country | Vaccines in development | Commercial vaccines |
|-------|----------------|-------------------------|---------------------|
| TGEV  | North America  | Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccine | Live attenuated vaccines (mono, bi- and trivalent for TGEV, rota and E.coli) |
|       | Europe         |                         | Inactivated vaccines (mono, bi- and trivalent for TGEV, rota and E.coli) |
| PEDV  | Asia           | Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine | Inactivated vaccines (mono, bi- and trivalent for TGEV, rota and E.coli) |
|       | North America  | Recombinant proteins expressed in yeast and baculovirus; DNA vaccine; infectious clone for live-attenuated vaccine | Inactivated vaccines; Recombinant alphavirus-based vaccine |
|       | Europe         | DNA vaccine              | Live attenuated vaccine (TR-13) |
|       | Asia           | Recombinant vaccines expressed in baculovirus, yeast, plants, *Lactobacillus casei*, *Salmonella Typhimurium* and others | Live attenuated vaccine (South Korea, PEDV strain SM98-1)|

5. Vaccines for PEDV in North America

The first vaccine for PEDV in the US was developed by Harris vaccines™ in Iowa, and conditionally licensed in 2013. The vaccine, initially called iPED vaccine, was based on a truncated version of the PEDV spike gene produced in the SirraVax™ RNA Particle Technology platform (Mohler et al., 2014b), which is based on the a pVEK replicon vector derived from the Venezuelan equine encephalitis virus. The technology is a propagation defective, single cycle RNA particle technology that is believed to target dendritic cells. A longer version of the spike genes was codon optimized and used in the second-generation vaccine called iPED plus, which now is commercially available as Porcine Epidemic Diarrhea Vaccine, RNA (PEDV RNA). The vaccine induced immunity in young pigs after two doses given intramuscularly in a three-week interval. Vaccinated weaned pigs when challenged with homologized gut tissue from a clinical isolate displayed significantly reduced severity of clinical signs (diarrhea) and reduced viral shedding for the first 72 h (Mohler et al., 2014a). Vaccine efficacy was further tested in naïve sows. After three vaccinations at 8, 5, and 1 weeks pre-farrowing piglets from both groups were challenged between 2 and 6 days of age with $10^5$ TCID<sub>50</sub> PEDV/CO/2013. Average litter mortality in the control group was 91%, while average mortality in the vaccinated groups was 69% (Crawford et al., 2015). Similar results were found in sows previously exposed to PEDV. After oral challenge of piglets within the first week average litter mortality was reduced from 59% in the control group to 45% in the vaccinated group. Finally, Greiner et al. (2015) evaluated the vaccine in 80 sows that had been previously exposed to PEDV. Vaccination induced higher titers against the S1 protein in the colostrum of vaccinated sows and reduced overall pig mortality by 3% (Greiner et al., 2015).

A second vaccine for PEDV in the US was developed by Zoetis and made commercially available in 2014 under a conditional license. The vaccine consists of an inactivated whole virus formulated with an adjuvant. The vaccine was tested in PEDV negative sows, which were vaccinated twice, 3 weeks apart, with the vaccine (n = 23) or an adjuvant placebo (n = 3). The vaccine was safe and immunogenic and induced neutralizing antibodies to both the whole virus and the spike protein (Frederickson et al., 2014). The vaccine was also tested under field conditions in a PEDV positive commercial herd. Sows (n = 120) were vaccinated at 5- and 2 weeks pre-farrowing, control sows (n = 120) received placebo. Vaccination resulted in reduction of pre-weaning mortality due to PEDV from 6.3% in piglets born to control sows versus 0.6% in piglets born to vaccinated sows. Vaccination resulted in about 3 times higher neutralization antibody titers compared to the control group, and an additional 1.8 pigs per sows survived (Rapp-Gabrielson et al., 2014).

A third vaccine was recently developed by the Vaccine and Infectious Disease Organization-InterVac in Canada. The vaccine is based on inactivated virus formulated with an adjuvant. When administered to seronegative sows 4 and 2 weeks prior to farrowing, high levels of neutralizing antibodies against PEDV were found in colostrum and milk, as well as in the serum of piglets born to vaccinated sows. Piglets were orally infected at 5 days of life with 300 pfu of PEDV isolate CO 025. It was found that 95% of all piglets (n = 83) born to vaccinated sows survived the infection and showed significantly reduced clinical symptoms, weight loss and viral shedding. In contrast, all piglets from unvaccinated sows displayed severe clinical symptoms including weight loss and dehydration, and 50% of these piglets died within 6 days post infection. These results were confirmed in two additional clinical trials. A large field trial involving >600 sows was performed in three commercial units in Saskatchewan, Canada to assess the vaccine in different genetics, health status and management systems. The vaccine demonstrated to be completely safe to use; no adverse events including injection site reactions and reproducive complications were observed. Vaccine efficacy was evaluated in 8% of these animals by transporting the pregnant sows a week before farrowing to the VIDO-InterVac high containment facility. Following oral challenge at 5 days of age, survival was significantly higher in piglets born to vaccinated sows than those from control sows (Berube et al., 2015). The assessment of duration of immunity is currently ongoing. In addition, an affinity tagged PEDV S1 protein was expressed in the HEK293 system to be used as subunit vaccine. When administered to pregnant sows the vaccine partially protected newborn piglets against infection with PEDV (Makadiya et al., 2016).

6. PEDV vaccines in Asia

Since early 1980s, PEDV outbreaks have been reported in several Asian countries, including China, Japan, Thailand, Taiwan, the Philippines, South Korea and Vietnam. In October 2010, a large-scale outbreak of severe PEDV was reported in China (Wang et al., 2013). In late 2013, PEDV outbreaks occurred in Japan, South Korea and Taiwan (Lee and Lee, 2014). Phylogenetic analysis of PEDV full-length genomic sequences reveals that PEDV can be genetically divided into 2 groups: G1 (classical) and G2 (field epidemic or pandemic). Each group can be further divided into two subgroups: 1a and 1b, 2a and 2b, respectively. It is also possible that the low to moderate effectiveness of current PEDV vaccines are due to genetic differences between vaccine and field epidemic strains (Kim et al., 2015).
For disease control, an inactivated bivalent TGEV and PEDV vaccine was introduced in China in 1995. In March 2015, a trivalent attenuated vaccine (PEDV, TGEV and porcine rotavirus) was also approved. All these vaccines were based on the classical CV777 (G1-a) strain that can be grown to high titers in green monkey kidney Vero cells. There are no data published on the efficacy of these vaccines. However, de Arriba et al. (de Arriba et al., 2002) orally inoculated 11-day-old conventionally reared piglets with two different doses of the attenuated CV-777 strain and challenged with the same virulent PEDV strain three weeks later. The vaccinated piglets were partially protected against the challenge, and 25% of the low dose- and 50% of the high dose-exposed pigs did not shed virus after challenge.

Since winter of 2010, China experienced severe PED outbreaks with devastating damage to the swine industry. These outbreaks can be explained by re-emergence of new PEDV strains. To answer industry demand, Chinese researchers have developed a bivalent (PEDV and TGEV) attenuated vaccine that contained the PEDV strain ZJ08 (G1-b) and a bivalent attenuated vaccine based on the AJ1102 strain (G2-b). Inactivated bivalent vaccine based on the G2-b strain has also been developed. These vaccines are currently under clinical evaluation (Wang et al., 2016).

In Japan, PEDV strain B3P-5 (G1-a) was attenuated after 100 passages in Vero cells (Sato et al., 2011). Subsequently, this strain has been employed as an intramuscular (IM) live attenuated vaccine (P-5 V) in Japan and South Korea. In addition, two South Korean virulent PEDV strains (SM98-1 and DR-13) were attenuated by serial cell culture passages. The attenuated SM98-1 strain has been used as an IM live or killed vaccine, whereas DR-13 was used as an oral live vaccine. This oral vaccine was registered and commercialised in the Philippines in 2011. In South Korea, the multiple dose vaccination program (3 or 4 IM vaccinations in the following order: live-killed–killed or live-live-killed, respectively) at 2- or 3-week intervals starting before farrowing is commonly recommended in pregnant sows (Lee, 2015).

According to a South Korean study, the administration of commercial vaccines increased the survival rate of piglets challenged with a virulent wild-type PEDV from 18.2% to over 80%. However, all vaccines did not significantly reduce morbidity rate and virus shedding (Lee, 2015). Also, Song et al. (Song et al., 2007) reported 60% reduction of the mortality rate of the suckling piglets born to the sows that were IM vaccinated with DR-13 PEDV vaccine.

Despite of nationwide use of commercially available vaccines, South Korea experienced a devastated PED epidemic in 2013–2014. PEDV G2-b strains were responsible for recent severe PED epidemics in Asian countries and North America. Considering this fact, South Korean researchers (Baek et al., 2016) tested an inactivated vaccine based on serially cultured G2-b strain KOR/KNU-141112/2014. Pregnant sows were immunised IM with the inactivated adjuvanted vaccine at 6 and 3 weeks prior to farrowing. Six-day old piglets were challenged with the homologous virulent virus. Piglets born to vaccinated sows had reduced morbidity, mortality and quickly recovered daily weight gain. Further studies are needed to evaluate efficacy of this vaccine in 1- or 2-day old piglets under field conditions.

All commercially available vaccines that are in use in Asia are traditional live attenuated or killed vaccines. However, researchers are working on the next-generation vaccines for PEDV (Table 1). For instance, Hou et al. (Hou et al., 2007) expressed the PEDV N protein on the surface of lactobacillus. Oral and intranasal inoculations of recombinant L casei into pregnant sow and mice resulted in high levels of N-specific serum IgG and mucosal IgA. Similarly, Liu et al. (Liu et al., 2012) expressed S1 and N protein in recombinant L casei and reported enhanced mucosal and systemic immune responses after oral immunization of mice. Meng et al. (Meng et al., 2013) evaluated the immunogenicity of recombinant DNA plasmids expressing S genes from PEDV and TGEV in mice. The results showed that the recombinant DNA plasmids increased the proliferation of T lymphocytes and the number of CD4+ and CD8+ T lymphocytes. In addition, the DNA vaccines induced a high level of IFN-γ in the immunized mice. At 35 days post-immunization, the recombinant DNA plasmids bearing full-length S genes of TGEV and PEDV stimulated high levels of virus-neutralizing antibodies. Zhang et al. (Zhang et al., 2016b) have also constructed bivalent DNA vaccine co-expressing S genes of TGEV and PEDV. Attenuated Salmonella Typhimurium was used for oral delivery this vaccine into pigs. Vaccinated pigs developed TGEV and PEDV-specific cellular and humoral immune responses; however, challenge experiment was not conducted in this study.

There have also been reports on expressing recombinant PEDV S protein fragments in plants (Bae et al., 2003) and in a cell line (Oh et al., 2014). Feeding mice with transgenic tobacco plants that express the S protein fragment containing the PEDV neutralizing epitope induced PEDV-specific antibody and cell-mediated immune responses. In another study, Oh et al. (Oh et al., 2014) established porcine cell line stably expressing S1 fragment of the PEDV spike protein. Pregnant sows were immunized IM 3 times with the purified and adjuvanted protein 6, 4 and 2 weeks prior to farrowing. The sows developed PEDV-specific neutralizing antibody response in serum and colostrum. One 4- to 5-day-old piglet was selected randomly from each farrowing sow for challenge with virulent PEDV. The piglets born to vaccinated sows showed reduced morbidity, mortality and virus shedding. However, a low number of challenged piglets hamper the author's conclusion about efficient protection of neonatal piglets.

7. Future perspectives

With the disappearance of TGEV around the world, the need for TGEV vaccines has dropped over the last few years. For North America and Europe, only two major international animal health companies continue to offer TGEV vaccines. In contrast, many parts of Asia including China and Korea are still dealing with TGEV outbreaks, and different types of vaccines are still available. The introduction of PEDV into the North American herd in 2013–2014, however, has reversed this picture and has highlighted the global need for effective vaccines. Coronaviruses represent an important group of animal pathogens that can have devastating impacts in a variety of species. For an industry to rely on biosecurity alone seems somewhat risky and, in case of an emerging disease, can lead to major economic losses, as witnessed in North America over the last two years. Indeed, the phylogeny of coronaviruses demonstrates a great deal of diversity in antigenic variants, which may lead to limited cross-protection against infection with different strains. Thus, it is important to continue to survey novel PEDV variants that may emerge locally or globally through antigenic drift (point mutations) or antigenic shift (recombination events).

Effective prevention and control of PEDV and other coronaviruses can only be achieved through the use of vaccines. An ideal vaccine prevents mortality and clinical disease in newborn piglets, the age group most seriously affected by the disease, as well as viral shedding. As lactogenic immunity is a key mechanism of protection, efforts to enhance the levels of antibodies in the milk through formulation (adjuvants) and delivery (mucosal) are critical. However, time is also of essence when dealing with a new strain, as traditional manufacturing vaccine methods like virus isolation, inactivation or attenuation can be time-consuming. Therefore, research on next-generation vaccines such as RNA particle, DNA, sub-unit and viral-vectored approaches is critical for
the prevention of future outbreaks of emerging coronaviruses.

Conflict of interest statement
The authors declare no conflict of interest.

References
Bae, J.L., Lee, J.G., Kang, T.J., Jang, H.S., Jang, Y.S., Yang, M.S., 2003. Induction of antigen-specific systemic and mucosal immune responses by feeding animals transgenic plants expressing the antigen. Vaccine 21, 4052–4058.
Baek, P.S., Choi, H.W., Lee, S., Yoon, I.J., Lee, Y.J., Lee du, S., Lee, C., 2016. Efficacy of an inactivated genotype 2b porcine epidemic diarrhea virus vaccine in neonatal piglets. Vet. Immunol. Immunopathol. 174, 45–52.
Bandy, M.R., Tao-Yang, G., Zhai, L., Zhao, Y., Hao, Y., Sheng, Z., Ding, X., Zhao, X., 2015. Porcine epidemic diarrhea virus uses cellular-surface heparan sulfate as an attachment factor. Arch. Virol. 160, 1621–1628.
Saif, I.J., Bohl, E.H., 1979. Passive immunity in transmissible gastroenteritis of swine: immunoglobulin classes of milk antibodies after oral-intranasal inoculation of sows with a live low cell culture-passaged virus. Am. J. Vet. Res. 40, 115–117.

Saif, I.J., Bohl, E.H., 1983. Passive immunity to transmissible gastroenteritis virus: intramammary viral inoculation of sows. Ann. N. Y. Acad. Sci. 409, 708–723.

Saif, I.J., 2004. Animal coronavirus vaccines: lessons for SARS. Dev. Biol. (Basel) 119, 129–140.

Salmon, H., Berri, M., Gerds, V., Meurens, F., 2009. Humoral and cellular factors of maternal immunity in swine. Dev. Comp. Immunol. 33, 384–393.

Sang, Y., Rowland, R.R., Hesse, R.A., Blecha, F., 2010. Differential expression and activity of the porcine type I interferon family. Physiol. Genomics 42, 248–258.

Sang, Y., Bergkamp, J., Blecha, F., 2014. Molecular evolution of the porcine type I interferon family: subtype-specific expression and antiviral activity. PLoS One 9, e112378.

Sato, T., Takeyma, N., Katsumata, A., Tuchiya, K., Kodama, T., Kusanagi, K., 2011. Mutations in the spike gene of porcine epidemic diarrhea virus associated with growth adaptation in vitro and attenuation of virulence in vivo. Virus Genes 43, 72–78.

Sestak, K., Meister, R.K., Hayes, J.R., Kim, L., Lewis, P.A., Myers, G., Saif, L.J., 1999. Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins. Vet. Immunol. Immunopathol. 70, 203–221.

Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeier, S., Whitemore, T.E., Kuestrin, R., Garrigues, U., Birks, C., Roraback, J., Ostrander, C., Dong, D., Shin, J., Pressnell, S., Fox, B., Haldeman, B., Cooper, E., Taft, D., Gilbert, T., Grant, F.J., Tackett, M., Kirwan, W., McKnight, G., Clegg, C., Foster, D., Klucher, K.M., 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63–68.

Song, D.S., Yang, J.S., Oh, J.S., Han, J.H., Park, B.K., 2003. Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. Vaccine 21, 1833–1842.

Song, D.S., Oh, J.S., Kang, B.K., Yang, J.S., Moon, H.J., Yoo, H.S., Jang, Y.S., Park, B.K., 2007. Oral efficacy of Vero cell attenuated porcine epidemic diarrhea virus DR13 strain. Res. Vet. Sci. 82, 134–140.

Tuboly, T., Nagy, E., 2001. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J. Gen. Virol. 82, 183–190.

Wang, K., Lu, W., Chen, J., Xie, S., Shi, H., Hsu, H., Yu, W., Xu, K., Bian, C., Fischer, W.B., Schwarz, W., Feng, L., Sun, B., 2012. PEDV ORF3 encodes an ion channel protein and regulates virus production. FEMS Lett. 586, 384–391.

Wang, J., Zhao, P., Guo, L., Liu, Y., Du, Y., Ren, S., Li, J., Zhang, Y., Fan, Y., Huang, B., Liu, S., Wu, J., 2013. Porcine epidemic diarrhea virus variants with high pathogenicity. China. Emerg. Infect. Dis. 19, 2048–2049.

Wang, D., Fang, L., Xiao, S., 2016. Porcine epidemic diarrhea in China. Virus Res., Wicht, O., Li, W., Willems, L., Meuleman, T.J., Wubbolts, R.W., van Kuppeveld, F.J., Rottier, P.J., Bosch, B.J., 2014. Proteolytic activation of the porcine epidemic diarrhea coronavirus spike fusion protein by trypsin in cell culture. J. Virol. 88, 7952–7961.

Wilson, E., Butcher, E.C., 2004. CCL28 controls immunoglobulin (Ig)A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate. J. Exp. Med. 200, 805–809.

Xu, X., Zhang, H., Zhang, Q., Dong, J., Liang, Y., Huang, Y., Liu, H.J., Dong, D., 2013a. Porcine epidemic diarrhea virus E protein causes endoplasmic reticulum stress and up-regulates interleukin-8 expression. Virol. J. 10, 26.

Xu, X., Zhang, H., Zhang, Q., Huang, Y., Dong, J., Liang, Y., Liu, H.J., 2013b. Porcine epidemic diarrhea virus N protein prolongs S-phase cell cycle, induces endoplasmic reticulum stress, and up-regulates interleukin-8 expression. Vet. Microbiol. 164, 212–221.

Yang, L.T., Peng, H., Zhu, Z.L., Li, G., Huang, Z.T., Zhao, Z.X., Koup, R.A., Bailer, R.T., Wu, C.Y., 2006. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 120, 171–178.

Yuan, X., Lin, H., Fan, H., 2015. Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein. Vaccine 33, 3900–3906.

Zhang, Q., Yoo, D., 2016. Immune evasion of porcine enteric coronaviruses and viral modulation of antiviral innate signaling. Virus Res., Zhang, Z., Chen, J., Shi, H., Chen, X., Shi, D., Feng, L., Yang, B., 2012. Identification of a conserved linear B-cell epitope in the M protein of porcine epidemic diarrhea virus. Virol. J. 9, 225.

Zhang, Q., Shi, K., Yoo, D., 2016a. Suppression of type I interferon production by porcine epidemic diarrhea virus and degradation of CREB-binding protein by nsp1. Virology 489, 252–268.

Zhang, Y., Zhang, X., Liao, X., Huang, X., Cao, S., Wen, X., Wen, Y., Wu, R., Liu, W., 2016b. Construction of a bivalent DNA vaccine co-expressing 5 genes of transmissible gastroenteritis virus and porcine epidemic diarrhea virus delivered by attenuated Salmonella typhimurium. Virus Genes 52, 354–364.

de Arriba, M.I., Carvajal, A., Pozo, J., Rubio, F., 2002. Mucoad and systemic isotype-specific antibody responses and protection in conventional pigs exposed to virulent or attenuated porcine epidemic diarrhoea virus. Vet. Immunol. Immunopathol. 85, 85–97.